Emerging COVID-19 Challenges: Long-COVID and Viral Variants
Emerging COVID-19 Challenges: Long-COVID and Viral Variants
This explainer is more than 90 days old. Some of the information might be out of date or no longer relevant. Browse our homepage for up to date content or request information about a specific topic from our team of scientists.
This article has been translated from its original language. Please reach out if you have any feedback on the translation.
A year into the global COVID-19 pandemic, physicians and researchers are battling two newly frustrating phenomena: the spread of novel coronavirus variants with potential to undermine patients’ immune-system defenses, and a mysterious long-lasting medical syndrome in survivors, for which there remains no definitive treatment. SciLine’s media briefing dove into the latest research on these biomedical challenges, and provided reporters with opportunities for Q&A.
A year into the global COVID-19 pandemic, physicians and researchers are battling two newly frustrating phenomena: the spread of novel coronavirus variants with potential to undermine patients’ immune-system defenses, and a mysterious long-lasting medical syndrome in survivors, for which there remains no definitive treatment. SciLine’s media briefing dove into the latest research on these biomedical challenges, and provided reporters with opportunities for Q&A.
Publication
What our experts say
Context and background
Resources
Media briefing
- Dr. Hana Akselrod, assistant professor of medicine at George Washington University School of Medicine and Health Sciences
- Dr. Christian Sandrock, professor of pulmonary and critical medicine at UC Davis School of Medicine
- Moderated by SciLine’s director, Rick Weiss
